Danmark - dansk - SEGES Landbrug & Fødevarer

borregaard bioplant - penetreringsolie - flydende middel - 1000 g/l penetreringsolie

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - solifenacinsuccinat, tamsulosinhydrochlorid - tabletter med modificeret udløsning - 6 mg+0,4 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - solifenacinsuccinat, tamsulosinhydrochlorid - tabletter med modificeret udløsning - 6 mg+0,4 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - solifenacinsuccinat, tamsulosinhydrochlorid - tabletter med modificeret udløsning - 6 mg+0,4 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - entecavir - hepatitis b, kronisk - antivirale midler til systemisk anvendelse - baraclude er indiceret til behandling af kronisk hepatitis b virus (hbv) infektion hos voksne med kompenseret leversygdom og dokumentation for aktiv viral replikation, vedvarende forhøjet serum-alanin aminotransferase (alt) niveauer og histologiske dokumentation for aktiv inflammation og/eller fibrose;dekompenseret leversygdom. for både erstatning og dekompenseret leversygdom, denne angivelse er baseret på data fra kliniske forsøg i nukleosid naive patienter med hbeag-positive og hbeag negativ hbv-infektion. med hensyn til patienter med lamivudin-ildfast hepatitis b.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, systemisk - immunosuppressiva - benlysta er angivet som add-on terapi til patienter i alderen 5 år og ældre med en aktiv, autoantibody positive systemisk lupus erythematosus (sle) med en høj grad af sygdommens aktivitet (e. positive anti-dsdna og lave supplement), på trods af standard-terapi. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiske midler - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. for yderligere oplysninger henvises der til afsnit 5.